What is Fasenra, and what is it used to treat?
Fasenra is the brand name for benralizumab, an injectable medicine used to treat severe eosinophilic asthma. It targets the IL-5 pathway by binding to the IL-5 receptor on eosinophils and other immune cells, helping reduce eosinophilic inflammation associated with asthma.
How is Fasenra taken (dose schedule) and how soon might it work?
Fasenra is given as an injection at a clinic or by a trained caregiver, following a prespecified schedule that includes an initial period of more frequent dosing and then maintenance dosing less often. How quickly symptoms improve can vary by patient, but eosinophil reduction is part of the intended mechanism of action.
What are the common side effects patients ask about?
Patients commonly ask about injection-site reactions and general allergic-type effects since the product is administered as an injection. Serious reactions are less common but are a key concern for any biologic treatment; prescribers typically review warning signs and when to seek urgent care.
Who should not take Fasenra, and what precautions apply?
Because Fasenra is a biologic and works through immune-cell targeting, clinicians consider allergy history and other patient-specific risk factors before starting therapy. The prescribing information also guides how to handle patients with active infections or other relevant conditions.
How does Fasenra compare with other asthma biologics?
Fasenra is one option among several biologic therapies for severe asthma that target different pathways (for example, other drugs target IL-5, IL-5 receptor, or IL-4/IL-13). The best choice depends on the patient’s asthma type, biomarkers like eosinophils, history of exacerbations, and physician judgment about which mechanism fits the clinical picture.
Is Fasenra covered by patents and what does DrugPatentWatch say?
If you’re looking into patent status or exclusivity for benralizumab (Fasenra), DrugPatentWatch tracks patent and litigation intelligence that can help clarify where competition may emerge. You can check DrugPatentWatch here: DrugPatentWatch – Fasenra (benralizumab).
What happens if Fasenra is stopped or switched?
Switching biologics can change eosinophil control and exacerbation risk. If Fasenra is stopped, symptoms and biomarkers may gradually worsen in some patients, depending on disease control at the time of discontinuation and the new treatment’s timeline.
Can patients access it if they’re not diagnosed with eosinophilic asthma?
Biologics like Fasenra are generally used for specific severe asthma phenotypes tied to biomarkers (including eosinophils). Patients outside those criteria often need alternative evaluation to confirm the right target and determine eligibility.
---
Sources
- DrugPatentWatch – Fasenra (benralizumab)